InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Q3 Operational Highlights and Advances AI-Driven Oncology Pipeline
November 18, 2026
Lantern Pharma (NASDAQ: LTRN) reported operational highlights and financial results for the third quarter ended Sept. 30, 2026, highlighting progress across its artificial intelligence (“AI”)-driven oncology pipeline and approximately $4 million in gross proceeds from financing completed at quarter end. In November, the company engaged its first clinical site to begin initial enrollment in a […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Publishes Phase 1a Glioblastoma Data, Advances LP-184 Combination Therapy Toward Phase 1b/2a Trial
November 10, 2026
Lantern Pharma (NASDAQ: LTRN) and its wholly owned subsidiary, Starlight Therapeutics, announced the publication of Phase 1a clinical data for LP-184 (zirdafulven), also being developed as STAR-001, in patients with recurrent glioblastoma (“GBM”). Published in the October 2026 issue of Cancer Research Communications, the study evaluated 16 patients and found LP-184 was generally well tolerated, […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Present at ThinkEquity Conference on Oct. 15
October 8, 2026
Lantern Pharma (NASDAQ: LTRN), an AI company developing targeted cancer therapies using its proprietary RADR (R) AI and machine learning platform, announced that management will present at the ThinkEquity Conference on Oct. 15, 2026, at 3:30 p.m. ET at the Mandarin Oriental in New York City. The presentation will be available via live webcast, and […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Receives Taiwan Approvals to Advance Phase 2 HARMONIC(TM) Trial
October 7, 2026
Lantern Pharma (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, received regulatory and Institutional Review Board “IRB” approvals in Taiwan to open Part 2 of its Phase 2 HARMONIC(TM) trial of LP-300. The lead Taiwan site is open to accrual and actively screening patients, while Lantern anticipates IRB approval at two additional sites during the […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Closes $4 Million Registered Direct Offering
October 1, 2026
Lantern Pharma (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, announced the closing of its previously announced registered direct offering of 3,669,725 shares of common stock, or pre-funded warrants in lieu thereof, at $1.09 per share. The offering generated approximately $4 million in gross proceeds […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Announces $4 Million Registered Direct Offering
September 29, 2026
Lantern Pharma (NASDAQ: LTRN) announced a definitive agreement for the purchase and sale of 3,669,725 shares of common stock, or pre-funded warrants in lieu thereof, at $1.09 per share in a registered direct offering expected to generate approximately $4 million in gross proceeds. In a concurrent private placement, the company will issue unregistered warrants to […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Present Open-Medicine AI Growth Plan, Live Platform Demo in Webinar
September 23, 2026
Lantern Pharma (NASDAQ: LTRN) will present the growth plan for Open-Medicine AI (“OMAI”), its wholly owned subsidiary developing a multi-agentic AI platform for drug development, during a live webinar today at 12:30 p.m. Eastern. CEO Panna Sharma will lead the 45-minute session, which will cover OMAI market opportunity, customer feedback, platform capabilities, development roadmap, economics, […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Receives USPTO Notice of Allowance for LP-284 Blood Cancer Treatment Patent
September 22, 2026
Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, announced that the United States Patent and Trademark Office (“USPTO”) issued a Notice of Allowance for U.S. Patent Application No. 18/500,032, covering methods of using LP-284 to treat mantle cell lymphoma (“MCL”), double-hit lymphoma (“DHL”) and other blood cancers. The allowed claims include LP-284 as a […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Host Webinar on Open-Medicine AI Platform, Business Model and Development Roadmap
September 17, 2026
Lantern Pharma (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, announced it will host a live webinar Sept. 23 at 12:30 p.m. Eastern to present the business model, development roadmap and value proposition of Open-Medicine AI (“OMAI”), its wholly owned subsidiary developing a multi-agentic AI platform […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Advances AI-Driven Oncology Pipeline, Establishes Open Medicine AI
August 14, 2026
Lantern Pharma (NASDAQ: LTRN), reported second-quarter 2026 operational and financial results, highlighting progress across its AI-driven oncology pipeline and the establishment of Open Medicine AI (“OMAI”) as a separate company. Emerging data from the Phase 2 HARMONIC(TM) trial showed LP-300’s progression-free survival benefit deepening with treatment duration in patients with EGFR exon 21 L858R mutations, […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Schedules Second-Quarter 2026 Results Webcast
August 7, 2026
Lantern Pharma (NASDAQ: LTRN), an artificial intelligence-driven oncology company, announced it will host a webcast to discuss its second-quarter 2026 operating and financial results on Aug. 14, 2026, at 9 a.m. ET. President and CEO Panna Sharma, joined by members of the management team, will review results for the quarter ended June 30, 2026, and provide […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) EMA Clears LP-184 Bladder Cancer Trial in Europe
July 28, 2026
Lantern Pharma (NASDAQ: LTRN) an AI-native precision oncology company, announced that the European Medicines Agency (“EMA”) has cleared an investigator-initiated Phase 1b/2 clinical trial evaluating lead drug candidate LP-184 (zirdafulven) in patients with advanced or metastatic bladder cancer. The biomarker-guided study, to be conducted at Rigshospitalet in Copenhagen, Denmark, will enroll up to 39 patients and […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Receives U.S. Patent Allowance for LP-184 Biomarker-Based Cancer Treatment Methods
July 23, 2026
Lantern Pharma (NASDAQ: LTRN) announced the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application covering methods of selecting and treating patients with ovarian, primary liver, kidney and thyroid cancers using its investigational therapy LP-184 (zirdafulven) based on a three-gene biomarker signature. The allowed claims cover the use of elevated expression of […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Launches AI-Powered ZetaOmics Computational Biology Platform
July 8, 2026
Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, has launched ZetaOmics, the computational biology module of its multi-agentic AI co-scientist platform, withZeta.ai, introducing an autonomous “Computational Biologist” agent designed to perform end-to-end bioinformatics and multi-omic analysis across cancer types. Initially available through an early-access program for select academic, industry and company collaborators, the platform is designed to automate […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Phase 2 HARMONIC Trial Data Supporting LP-300 in EGFR-Mutant Lung Cancer
June 2, 2026
Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, reported updated Phase 2 HARMONIC trial data showing that LP-300, in combination with carboplatin and pemetrexed, demonstrated a progression-free survival benefit that increased with treatment duration in patients with EGFR Exon 21 L858R-mutant non-small cell lung cancer who had progressed following TKI therapy. The emerging data […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Receives FDA Support for HARMONIC(TM) Trial Amendments in Never-Smoker NSCLC
May 19, 2026
Lantern Pharma (NASDAQ: LTRN) announced that the U.S. Food and Drug Administration raised no objections to proposed protocol amendments for the ongoing Phase 2 HARMONIC(TM) trial evaluating LP-300 in never-smokers with advanced non-small cell lung cancer adenocarcinoma. The company said the FDA’s written response to its Type C meeting request provides a clearer regulatory path […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Q1 2026 Results, Advances Clinical Pipeline and AI Commercialization Strategy
May 18, 2026
Lantern Pharma (NASDAQ: LTRN) a clinical-stage AI-driven precision oncology company, reported first-quarter 2026 operational highlights and financial results, highlighting a 47% year-over-year reduction in research and development spending while advancing multiple clinical programs through key regulatory milestones, including a successful FDA Type C meeting outcome for the Phase 2 HARMONIC trial of LP-300 and IND clearance […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Closes $4.4 Million Registered Direct Offering
May 15, 2026
Lantern Pharma (NASDAQ: LTRN) announced the closing of its previously announced registered direct offering, raising approximately $4.4 million in gross proceeds through the sale of 2,135,923 shares of common stock, or pre-funded warrants in lieu thereof, at $2.06 per share. In a concurrent private placement, the company also issued unregistered warrants to purchase up to […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Enters $4.4 Million Registered Direct Offering
May 13, 2026
Lantern Pharma (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, announced a definitive agreement for the purchase and sale of 2,135,923 shares of common stock, or pre-funded warrants in lieu thereof, at $2.06 per share in a registered direct offering expected to generate approximately $4.4 million in gross proceeds. The company also announced a concurrent […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Report First Quarter 2026 Financial Results May 15
May 12, 2026
Lantern Pharma (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, announced that it will report its first-quarter 2026 operating and financial results via press release on May 15. The update will include financial results for the quarter ended March 31, 2026, along with operational updates regarding the company’s clinical trials and development of its proprietary artificial intelligence and […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Expands withZeta.ai Roadmap With Multi-Agent AI and Computational Biology Tools
May 7, 2026
Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, unveiled the next phase of development for its withZeta.ai platform, including planned launches of ZetaSwarm(TM), an autonomous multi-agent AI research system, ZetaOmics(TM), a computational biology and multi-omic analytics toolkit, and new enterprise-grade capabilities designed to support institutional oncology research and drug discovery workflows. To view the […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Expands predictBBB Platform Into Large Quantitative Model for Drug Discovery
April 29, 2026
Lantern Pharma (NASDAQ: LTRN) announced the expansion of its predictBBB(TM) platform into a Large Quantitative Model (LQM), delivering a real-time, web-based molecular intelligence engine that enables researchers to generate comprehensive developability profiles for small molecules from a single SMILES input. The enhanced platform leverages Lantern’s RADR(R) AI technology to provide rapid, high-dimensional analysis across physicochemical […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Host Live Public Demo of withZeta.ai AI Co-Scientist Platform
April 24, 2026
Lantern Pharma (NASDAQ: LTRN) announced it will host its first live, public demonstration of its withZeta.ai multi-agentic AI co-scientist platform on April 30, 2026, with two sessions scheduled to accommodate global audiences. The event will feature a real-time, interactive demonstration led by CEO Panna Sharma, showcasing the platform’s ability to execute complex oncology research workflows by integrating clinical, molecular and scientific datasets. Lantern said […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Schedules FDA Type C Meeting For HARMONIC Trial Amendments
April 20, 2026
Lantern Pharma (NASDAQ: LTRN) announced it has scheduled a mid-May 2026 Type C meeting with the U.S. Food and Drug Administration to seek feedback on proposed protocol amendments to its Phase 2 HARMONIC(TM) trial evaluating LP-300 in non-small cell lung cancer. The proposed changes include focusing enrollment on EGFR Exon 21 L858R patients, shifting to a […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Launches withZeta.ai Platform, Opens New Revenue Stream
April 14, 2026
Lantern Pharma (NASDAQ: LTRN) announced the commercial launch of withZeta.ai, its multi-agentic AI co-scientist platform for rare cancer drug discovery, with subscriptions now available across academic and commercial tiers, creating a new non-dilutive revenue stream for the company. The platform, built from Lantern’s RADR (R) oncology-focused AI technologies, will be showcased at a private investor event […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Host April 9 Investor Briefing Featuring Live Demo Of withZeta.ai Platform
April 2, 2026
Lantern Pharma (NASDAQ: LTRN) announced it will host an investor, analyst and shareholder briefing on April 9, 2026, at 8:30 a.m. Eastern, featuring a live demonstration of withZeta.ai, described as the first multi-agentic AI co-scientist for rare cancer drug discovery, development and clinical trial design. The webcast will highlight the platform’s capabilities, commercial architecture, competitive […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Advances AI-Driven Oncology Pipeline With Multiple 2026 Milestones in View
March 31, 2026
Lantern Pharma (NASDAQ: LTRN) reported fourth-quarter and full-year 2025 operational highlights led by continued progress in its LP-300 Phase 2 HARMONIC trial, completion of targeted enrollment in Japan, planned protocol discussions with the FDA in mid-May 2026 and advancement of LP-184, LP-284 and STAR-001 across multiple oncology indications. The company said its AI-driven portfolio now […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Receives FDA Clearance For STAR-001 Pediatric CNS Cancer Trial
March 27, 2026
Lantern Pharma (NASDAQ: LTRN) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for STAR-001, enabling a planned Phase 1 pediatric clinical trial targeting relapsed or refractory central nervous system malignancies. The study, to be conducted with the POETIC consortium across leading pediatric cancer centers, will evaluate STAR-001 alone […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Schedules Fourth Quarter And Fiscal Year 2025 Results Webcast
March 24, 2026
Lantern Pharma (NASDAQ: LTRN) will host a webcast to discuss its fourth quarter and fiscal year 2025 operating and financial results on March 30 at 4:30 p.m. Eastern Time. Management, led by President and Chief Executive Officer Panna Sharma, will review results for the period ended Dec. 31, 2025 and provide updates on upcoming milestones, […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Present AI-Driven Neuro-Oncology Strategy at Glioblastoma Summit
February 10, 2026
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence to accelerate oncology drug discovery and development, announced that Chief Executive Officer and President Panna Sharma will present at the 7th Glioblastoma Drug Development Summit, taking place Feb. 17–19, 2026, in Boston. During a Day Two presentation on Feb. 19, Mr. Sharma will highlight how the Company’s RADR® […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Receives FDA Orphan Drug Designation For LP-284 In Soft Tissue Sarcomas
January 20, 2026
Lantern Pharma (NASDAQ: LTRN) announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to LP-284 for the treatment of soft tissue sarcomas, marking the third orphan designation for the program and the sixth overall across the company clinical pipeline. The designation expands LP-284 beyond hematologic malignancies into solid tumors and reflects its synthetic […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Establishes AI Center of Excellence and Advanced Agentic Labs in India
January 12, 2026
Lantern Pharma (NASDAQ: LTRN) announced the establishment of an A.I. Center of Excellence and Advanced Agentic Labs in Bengaluru, India, marking a strategic inflection point as the company moves to industrialize its AI-enabled drug discovery capabilities at global scale. The Bengaluru hub will serve as Lantern’s global scale-up center for its proprietary “RADR (R)” AI […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Details Encouraging LP-184 Phase 1a Results Showing Durable Disease Control in Advanced Solid Tumors
December 3, 2025
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company using artificial intelligence and genomics to transform oncology drug development, reported additional details and clinical insights from its completed Phase 1a dose-escalation study of LP-184 along with highlights from a recent webinar. The study in 63 heavily pre-treated patients with advanced solid tumors met all primary endpoints […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Q3 2025 Results and Highlights AI-Driven Clinical Progress
November 13, 2025
Lantern Pharma (NASDAQ: LTRN) reported third-quarter 2025 results and advanced multiple AI-driven oncology programs, highlighted by completion of enrollment and achievement of all primary endpoints in the LP-184 Phase 1a trial, which showed a 48% clinical benefit rate at or above the therapeutic dose threshold along with a favorable safety profile and strong biomarker correlations. […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) CEO Discusses AI-Driven Cancer Drug Development in FintechTV Interview at NYSE
November 10, 2025
• Lantern’s AI platform “learns, reads, models, and predicts” to identify new drugs and indications • CEO Panna Sharma says AI is compressing development timelines and cost structures across oncology Lantern Pharma (NASDAQ: LTRN), an AI-driven cancer drug developer, is using large-scale machine learning to discover new therapies, reposition existing molecules, and target high-unmet-need oncology indications. […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Sets Nov. 13 Webcast to Review Q3 2025 Results and AI Platform Developments
November 6, 2025
Lantern Pharma (NASDAQ: LTRN), an AI-driven company developing targeted cancer therapies through its proprietary RADR(R) platform, will host a webcast at 9 a.m. ET (6 a.m. PT) on Thursday, Nov. 13, 2025, to review third-quarter operating and financial results. President and CEO Panna Sharma and other members of the management team will discuss quarterly performance, […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Present AI Drug Discovery Platforms at Inaugural AI4BM Symposium
October 30, 2025
Lantern Pharma (NASDAQ: LTRN) will present its commercially deployed AI research platforms, predictBBB.ai and LBx-AI, at the inaugural AI for Biology and Medicine symposium hosted by the University of North Texas. The company will showcase how machine learning is accelerating drug development and precision oncology, including 94.1% accuracy in predicting blood-brain barrier permeability and 86% […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Complete Metabolic Response in Phase 1 LP-284 Trial at LL&M Congress
October 28, 2025
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its RADR(R) AI platform to transform oncology drug discovery and development, presented clinical data from its ongoing Phase 1 trial of LP-284 at the 25th Annual Lymphoma, Leukemia & Myeloma Congress in New York City, showing a confirmed complete metabolic response in a 41-year-old patient with […]
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Present at ThinkEquity Conference on Oct. 30
October 24, 2025
Lantern Pharma (NASDAQ: LTRN), an artificial intelligence (AI) company focused on developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery, announced that its management team will present at the ThinkEquity Conference on Thursday, Oct. 30, 2025, at 11:30 a.m. ET at the Mandarin Oriental in New York. To view the […]
InvestorNewsBreaks – Lantern Pharma Inc. (NASDAQ: LTRN) Advancing Drug Discovery with PredictBBB.ai(TM) Partnership
October 22, 2025
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotech company, has partnered with Hoth Therapeutics (NASDAQ: HOTH) to deploy its AI-powered platform, PredictBBB.ai(TM), in streamlining drug development. The platform, boasting 94% accuracy, predicts whether drug candidates can cross the blood-brain barrier—a major challenge in developing treatments for neurological conditions. By integrating PredictBBB.ai(TM), Hoth aims to reduce development […]